ArticleThe World Allergy Organization journal2025
Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts of
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-World Effectiveness and Safety of Allergen Immunotherapy with a Combination of Glutaraldehyde-Polymerized Allergen Extracts ofInternational journal of molecular sciences · 2026Article
- Real-World Effectiveness of Polymerized House-Dust-Mite Subcutaneous Immunotherapy up to 24 Months: Why Baseline Symptom Severity Shapes Measurement of the Combined Symptom-Medication Response.Journal of clinical medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subcutaneous allergen immunotherapy (SCIT) is recognized as an effective and safe treatment for children and adults suffering from allergic respiratory diseases driven by house dust mites (HDM) in tropical regions. Objectives: To assess the clinical effectiveness and safety of SCIT using glutaraldehyde-polymerized allergen extracts of Methods: A retrospective, observational study including 49 children diagnosed with HDM-induced allergic rhinitis, with or without asthma, who were treated with SCIT for 1 year. Primary endpoints were measured using the Combined Symptom and Medication Score (CSMS). Secondary outcomes were asthma medication use and Asthma Control Test (ACT) scores. Results: Significant improvement in CSMS (median reduction: -0.8; p = 0.015) and ACT scores (median increase: -1.3; p = 0.015) were observed within 3 months; 76% of patients had at least a 20% of reduction of the CSMS compared to baseline after 6 months with immunotherapy (IT). Medication use for asthma decreased significantly after 1 year (p = 0.035). Conclusion: SCIT using polymerized HDM extracts demonstrated to be effective and safe in allergic pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.